(Q36007647)

English

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism (English)

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1 reference

based on heuristic

inferred from title

Sigitas Verselis

6

object named as

Sigitas Verselis

0 references

10

object named as

Xavier Leleu

0 references

Kenneth C. Anderson

14

object named as

Kenneth C Anderson

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

author name string

Evdoxia Hatjiharissi

1

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Lian Xu

2

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Daniel Ditzel Santos

3

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Zachary R Hunter

4

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Bryan T Ciccarelli

5

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Michael Modica

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Yang Cao

8

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Robert J Manning

9

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Elizabeth A Dimmock

11

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Alexandros Kortsaris

12

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Constantine Mitsiades

13

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Edward A Fox

15

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Steven P Treon

16

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

language of work or name

0 references

publication date

2 May 2007

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

110

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

7

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

2561-2564

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1988936

2 October 2017

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1988936

2 October 2017

A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1988936

2 October 2017

Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1988936

2 October 2017

A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1988936

2 October 2017

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1988936

11 July 2018

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1988936

23 September 2018

Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1988936

23 September 2018

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1988936

23 September 2018

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1988936

23 September 2018

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1988936

23 September 2018

Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17475906

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

1 reference

https://pubmed.ncbi.nlm.nih.gov/17475906

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Binding of monomeric human IgG defines an expression polymorphism of Fc gamma RIII on large granular lymphocyte/natural killer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17475906

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17475906

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2007-01-070656

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36007647&oldid=1561121178"